Search

Your search keyword '"Le Ngoc Dung"' showing total 12 results
Start Over Author "Le Ngoc Dung" Publication Year Range Last 3 years
12 results on '"Le Ngoc Dung"'

1. Corrigendum: Heparin binding epidermal growth factor–like growth factor is a prognostic marker correlated with levels of macrophages infiltrated in lung adenocarcinoma

Author

Nguyen Van Hiep, Wei-Lun Sun, Po-Hao Feng, Cheng-Wei Lin, Kuan-Yuan Chen, Ching-Shan Luo, Le Ngoc Dung, Hoang Van Quyet, Sheng-Ming Wu, and Kang-Yun Lee

Subjects
heparin-binding EGF-like growth factor (HBEGF), bioinformatics, biomarker, immune infiltration, macrophage chemotaxis, non-small cell lung cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2022
Full Text
View/download PDF

2. Heparin binding epidermal growth factor–like growth factor is a prognostic marker correlated with levels of macrophages infiltrated in lung adenocarcinoma

Author

Nguyen Van Hiep, Wei-Lun Sun, Po-Hao Feng, Cheng-Wei Lin, Kuan-Yuan Chen, Ching-Shan Luo, Le Ngoc Dung, Hoang Van Quyet, Sheng-Ming Wu, and Kang-Yun Lee

Subjects
heparin-binding EGF-like growth factor (HBEGF), bioinformatics, biomarker, immune infiltration, macrophage chemotaxis, non-small cell lung cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

BackgroundThe interactions between tumor cells and the host immune system play a crucial role in lung cancer progression and resistance to treatment. The alterations of EGFR signaling have the potential to produce an ineffective tumor-associated immune microenvironment by upregulating a series of immune suppressors, including inhibitory immune checkpoints, immunosuppressive cells, and cytokines. Elevated Heparin-binding EGF-like growth factor (HB-EGF) expression, one EGFR ligand correlated with higher histology grading, worse patient prognosis, and lower overall survival rate, acts as a chemotactic factor. However, the role of heparin-binding epidermal growth factor-like growth factor (HB-EGF) in the accumulation of immune cells in the tumor microenvironment remains unclear.MethodsThe clinical association of HB-EGF expression in lung cancer was examined using the Gene Expression Omnibus (GEO) repository. HB-EGF expression in different cell types was determined using single-cell RNA sequencing (scRNA-seq) dataset. The correlation between HB-EGF expression and cancer-immune infiltrated cells was investigated by performing TIMER and ClueGo pathways analysis from TCGA database. The chemotaxis of HB-EGF and macrophage infiltration was investigated using migration and immunohistochemical staining.ResultsThe high HB-EGF expression was significantly correlated with poor overall survival in patients with lung adenocarcinoma (LUAD) but not lung squamous cell carcinoma (LUSC). Moreover, HB-EGF expression was correlated with the infiltration of monocytes, macrophages, neutrophils, and dendritic cells in LUAD but not in LUSC. Analysis of scRNA-seq data revealed high HB-EGF expression in lung cancer cells and myeloid cells. Results from the pathway analysis and cell-based experiment indicated that elevated HB-EGF expression was associated with the presence of macrophage and lung cancer cell migration. HB-EGF was highly expressed in tumors and correlated with M2 macrophage infiltration in LUAD.ConclusionsHB-EGF is a potential prognostic marker and therapeutic target for lung cancer progression, particularly in LUAD.

Published
2022
Full Text
View/download PDF

5. Contributors

Author

Abdollah, Maha R.A., primary, Ahmad, Mir Hilal, additional, Alcover-Sanchez, Berta, additional, Alfaro Rodríguez, Alfonso, additional, Ali, Marwa A., additional, Alkadhi, Karim A., additional, Auburger, Georg, additional, Banerjee, Meheli, additional, Baums, Christoph G., additional, Belan, Daria V., additional, Bleeser, Tom, additional, Bobrovskaya, Larisa, additional, Bolay, Hayrunnisa, additional, Brandenburg, Joline E., additional, Budni, Josiane, additional, Burnsed, Jennifer, additional, Cadiz, Antonio, additional, Carlin, Katherine, additional, Chavez-Valdez, Raul, additional, Chen, Win Ning, additional, Coq, Jacques-Olivier, additional, Crocker, Stephen J., additional, Cubelos, Beatriz, additional, Darshini, I.S., additional, de Buhr, Nicole, additional, Debatisse, Justine, additional, Deng, Isaac, additional, Deprest, Jan, additional, Devroe, Sarah, additional, dos Santos, Maria Laura Cecconi, additional, Doszyn, Olga, additional, Dulski, Tomasz, additional, Eker, Omer Faruk, additional, Ekimova, Irina V., additional, Falquetto, Barbara, additional, Fernández, Ana, additional, Fogarty, Matthew J., additional, Fouda, Abdelrahman Y., additional, Gandía, Luis, additional, García, Antonio G., additional, González Maciel, Angélica, additional, Grandgirard, Denis, additional, Grayson, Bernadette E., additional, Greenberg, David A., additional, Gulyaeva, Natalia, additional, Gupta, Sangeetha, additional, Gürer, Bora, additional, Guzmán-Quevedo, Omar, additional, Gyamfi, Daniel, additional, Hamimi, Sarah, additional, He, Junqiu, additional, Hong, Sung-Ha, additional, Ida, Hiroyuki, additional, Jantrapirom, Salinee, additional, Jantzie, Lauren L., additional, Kadzhaya, Mykola, additional, Kanungo, Jyotshna, additional, Kaur, Ginpreet, additional, Keller, Gabriela Serafim, additional, Kelliny, Sally, additional, Kokiko-Cochran, Olga N., additional, Komoltsev, Ilia, additional, Kumar, P. Pramod, additional, Lacerda, Diego Cabral, additional, Lambert, Geoffrey A., additional, Lapshina, Ksenia V., additional, Largent-Milnes, Tally M., additional, Le, Ngoc Dung, additional, Leib, Stephen L., additional, Levine, Aidan A., additional, Li, Lulin, additional, Liktor-Busa, Erika, additional, Liu, Fang, additional, Liu, Sufang, additional, Luo, Jian, additional, Manhães-de-Castro, Raul, additional, McBride, Devin W., additional, Medeiros, Eduarda Behenck, additional, Meurer, Marita, additional, Miller, Brandon A., additional, Mondal, Amal Chandra, additional, Moreira, Thiago S., additional, Narayanan, S. Priya, additional, Nguyen, Andy, additional, Panteleichuk, Andrii, additional, Paricio, Nuria, additional, Pastukhov, Yuri F., additional, Patel, Vinood B., additional, Pedachenko, Eugene, additional, Perouansky, Misha, additional, Petriv, Taras, additional, Piccolo, Luca Lo, additional, Prashanth, K.V. Harish, additional, Preedy, Victor R., additional, Puig, Cristina, additional, Rajendram, Rajkumar, additional, Ramasamy, Ramalakshmi, additional, Ramasamy, Santhamani, additional, Ramirez-Lee, Manuel Alejandro, additional, Ray, Trenton J., additional, Rempel, Lisienny Campoli Tono, additional, Renz, Miriam, additional, Rex, Steffen, additional, Reynoso Robles, Rafael, additional, Ricci, Susanna, additional, Rieger, Sandra, additional, Robinson, Shenandoah, additional, Romero Velázquez, Rosa María, additional, Rümmler, Robert, additional, Sanz, Francisco José, additional, Savosko, Serhii, additional, Sedky, Nada K., additional, Sen, Nesli-Ece, additional, Shaikh, Mohd. Farooq, additional, Shan, Shengshuai, additional, Sharma, Uma, additional, Shmeleva, Anna, additional, Sieck, Gary C., additional, Siegert, Pascal, additional, Smith, Allie M., additional, Smith, Phillip P., additional, Solana-Manrique, Cristina, additional, Soulas, Emmanuelle Canet, additional, Subba, Rhea, additional, Subbian, Selvakumar, additional, Takakura, Ana C., additional, Talpos, John C., additional, Tam, Kin Yip, additional, Tao, Feng, additional, Tapp, Zoe, additional, Thawkar, Baban S, additional, Tolba, Mai F., additional, Toscano, Ana Elisa, additional, Tsuji, Masahiro, additional, Valenzuela, Ignacio, additional, Van de Velde, Marc, additional, Van der Veeken, Lennart, additional, Velíšek, Libor, additional, Velíšková, Jana, additional, Visco, Diego Bulcão, additional, Vita, Sydney M., additional, von Köckritz-Blickwede, Maren, additional, Vuralli, Doga, additional, Walters, Jennifer L., additional, Wassarman, David A., additional, Wateau, Océane, additional, Yamaguchi, Masamitsu, additional, Yoshida, Hideki, additional, Zhou, Xin-Fu, additional, and Zmorzynska, Justyna, additional

Published
2023
Full Text
View/download PDF

9. Experimental meningitis by Streptococcus pneumoniae and Neisseria meningitidis in rodents

Author

Le, Ngoc Dung, Ricci, Susanna, Grandgirard, Denis, and Leib, Stephen L

Subjects
570 Life sciences, biology, 610 Medicine & health
Abstract

Bacterial meningitis (BM) is a global public health issue that affects patients of all ages. The two leading causes of BM worldwide are Streptococcus pneumoniae (the pneumococcus) and Neisseria meningitidis (the meningococcus). Despite the use of antibiotics and vaccines, both pneumococcal meningitis (PM) and meningococcal meningitis (MM) result in high case fatality rates and long-term neurological sequelae. Moreover, increasing resistance to first-line antibiotics, limited vaccine coverage, serotype replacement in vaccinated population, and lack of adjunctive therapies to control brain damage are all matters of concern in the management of PM and MM. The availability of animal models of PM and MM is crucial to characterize the pathogenetic and pathophysiologic mechanisms of disease as well as to identify novel antimicrobial agents, adjuvant therapies and vaccine candidates. Historically, animal models of BM employed large animals to mimic the disease in humans, such as monkeys for MM and rabbits for PM. However, since the introduction of rodents, both rats and mice have demonstrated to be robust, reliable, and suitable species for modeling both PM and MM. Depending on the route of infection, the dose of bacterial inoculum, the animal age and strain, different experimental readouts are obtained that permit to answer specific scientific questions. This chapter describes the main features of two models of PM and MM developed in the infant rat and adult mouse, respectively. Each model system presents unique characteristics that allow to study different aspects of the disease. The broad range of different forms of brain injury that can be observed in the PM infant rat model enables to study the entire spectrum of the pathophysiology of brain damage in PM and allows to evaluate novel therapeutic strategies and their impact on long-term neurological sequelae. The MM mouse model is suitable to investigate the role of meningococcal virulence factors in the disease, the host–parasite interactions in the central nervous system, and the efficacy of drugs to control the infection and limit brain damage in MM.

Published
2023

11. Efficacy assessment of a novel endolysin PlyAZ3aT for the treatment of ceftriaxone-resistant pneumococcal meningitis in an infant rat model

Author

Valente, Luca G, Le, Ngoc Dung, Pitton, Melissa, Chiffi, Gabriele, Grandgirard, Denis, Jakob, Stephan M, Cameron, David R, Resch, Grégory, Que, Yok-Ai, and Leib, Stephen L

Subjects
570 Life sciences, biology, 610 Medicine & health
Abstract

BACKGROUND Treatment failure in pneumococcal meningitis due to antibiotic resistance is an increasing clinical challenge and alternatives to antibiotics warrant investigation. Phage-derived endolysins efficiently kill gram-positive bacteria including multi-drug resistant strains, making them attractive therapeutic candidates. The current study assessed the therapeutic potential of the novel endolysin PlyAZ3aT in an infant rat model of ceftriaxone-resistant pneumococcal meningitis. METHODS Efficacy of PlyAZ3aT was assessed in a randomized, blinded and controlled experimental study in infant Wistar rats. Meningitis was induced by intracisternal infection with 5 x 107 CFU/ml of a ceftriaxone-resistant clinical strain of S. pneumoniae, serotype 19A. Seventeen hours post infection (hpi), animals were randomized into 3 treatment groups and received either (i) placebo (phosphate buffered saline [PBS], n = 8), (ii) 50 mg/kg vancomycin (n = 10) or (iii) 400 mg/kg PlyAZ3aT (n = 8) via intraperitoneal injection. Treatments were repeated after 12 h. Survival at 42 hpi was the primary outcome; bacterial loads in cerebrospinal fluid (CSF) and blood were secondary outcomes. Additionally, pharmacokinetics of PlyAZ3aT in serum and CSF was assessed. RESULTS PlyAZ3aT did not improve survival compared to PBS, while survival for vancomycin treated animals was 70% which is a significant improvement when compared to PBS or PlyAZ3aT (p

Published
2022

12. Efficacy assessment of a novel endolysin PlyAZ3aT for the treatment of ceftriaxone-resistant pneumococcal meningitis in an infant rat model.

Author

Valente, Luca G., Le, Ngoc Dung, Pitton, Melissa, Chiffi, Gabriele, Grandgirard, Denis, Jakob, Stephan M., Cameron, David R., Resch, Grégory, Que, Yok-Ai, and Leib, Stephen L.

Subjects
*PNEUMOCOCCAL meningitis, *LIPOSOMES, *BLOOD-brain barrier, *MULTIDRUG resistance in bacteria, *ANIMAL disease models, *INFANTS, *INTRAPERITONEAL injections, *DRUG resistance in bacteria
Abstract

Background: Treatment failure in pneumococcal meningitis due to antibiotic resistance is an increasing clinical challenge and alternatives to antibiotics warrant investigation. Phage-derived endolysins efficiently kill gram-positive bacteria including multi-drug resistant strains, making them attractive therapeutic candidates. The current study assessed the therapeutic potential of the novel endolysin PlyAZ3aT in an infant rat model of ceftriaxone-resistant pneumococcal meningitis. Methods: Efficacy of PlyAZ3aT was assessed in a randomized, blinded and controlled experimental study in infant Wistar rats. Meningitis was induced by intracisternal infection with 5 x 107 CFU/ml of a ceftriaxone-resistant clinical strain of S. pneumoniae, serotype 19A. Seventeen hours post infection (hpi), animals were randomized into 3 treatment groups and received either (i) placebo (phosphate buffered saline [PBS], n = 8), (ii) 50 mg/kg vancomycin (n = 10) or (iii) 400 mg/kg PlyAZ3aT (n = 8) via intraperitoneal injection. Treatments were repeated after 12 h. Survival at 42 hpi was the primary outcome; bacterial loads in cerebrospinal fluid (CSF) and blood were secondary outcomes. Additionally, pharmacokinetics of PlyAZ3aT in serum and CSF was assessed. Results: PlyAZ3aT did not improve survival compared to PBS, while survival for vancomycin treated animals was 70% which is a significant improvement when compared to PBS or PlyAZ3aT (p<0.05 each). PlyAZ3aT was not able to control the infection, reflected by the inability to reduce bacterial loads in the CSF, whereas Vancomycin sterilized the CSF and within 25 h. Pharmacokinetic studies indicated that PlyAZ3aT did not cross the blood brain barrier (BBB). In support, PlyAZ3aT showed a peak concentration of 785 μg/ml in serum 2 h after intraperitoneal injection but could not be detected in CSF. Conclusion: In experimental pneumococcal meningitis, PlyAZ3aT failed to cure the infection due to an inability to reach the CSF. Optimization of the galenic formulation e.g. using liposomes might enable crossing of the BBB and improve treatment efficacy. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results